Based in Emeryville, California, Cell Design Labs is a pre-clinical stage company, focused on developing disruptive CAR-T and T cell receptor (TCR) therapies to advance discovery and development
The investment will support GSK’s research to generate genetic sequencing data from UK Biobank. GSK will sequence the data from all 500,000 volunteer participants following the first 50,000
The trial, dubbed MONALEESA-7, saw Kisqali, a CDK4/6 inhibitor, combined with an aromatase inhibitor or tamoxifen and goserelin as initial endocrine-based therapy pitted against endocrine therapy and goserelin alone.
Janssen Biotech, along with AbbVie’s Pharmacyclics, has developed Imbruvica, which is a first-in-class Bruton's tyrosine kinase inhibitor. iNNOVATE is a Pharmacyclics-sponsored, randomized, placebo-controlled and double-blind study designed to
The FDA has approved the once-weekly analogue of human glucagon-like peptide-1 (GLP-1) receptor agonist in 0.5mg and 1mg therapeutic dosages with the injection indicated to be used as
The investigational compound, which has been designed to selectively inhibit IL-23 by binding to its p19 subunit, was evaluated in the late-stage study dubbed IMMhance, In the first
A human monoclonal antibody, Repatha has been designed to suppress proprotein convertase subtilisin/kexin type 9 (PCSK9). It is now the first PCSK9 inhibitor to be approved in the
Sublocade’s approval is for patients who had started treatment with a transmucosal buprenorphine-containing product and have been on a stable dose of the treatment for at least seven
Erenumab delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study, dubbed Strive. Erenumab functions by targeting and inhibiting the Calcitonin Gene-Related Peptide
The trial showed statistically significant and dose dependent increases in lean body mass and less head following treatment with VK5211 compared against placebo. In addition, the study also reached secondary endpoints,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.